Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Kendall v. Odonate Therapeutics, Inc. et al
Case Number:
3:20-cv-01828
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
Sectors & Industries:
-
January 12, 2022
Court OKs Pharma Investors' $12.7M Deal Over Drug Trial
A California federal judge granted preliminary approval of the $12.7 million settlement between Odonate Therapeutics Inc. and investors on Wednesday, ending a class action that accused the pharmaceutical company of misleading investors by concealing information on a trial for a chemotherapy agent in development.
-
August 04, 2021
Odonate Therapeutics Can't Beat Investor Suit Over Drug Trial
Odonate Therapeutics Inc. can't shake a proposed securities class action accusing the pharmaceutical company of misleading investors by concealing information on a trial for a chemotherapy agent in development, after a California federal judge on Wednesday found that Odonate shareholders sufficiently alleged the company misled them.